Inhibrx Biosciences (INBX) vs Prime Medicine (PRME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Prime Medicine (PRME) has outperformed Inhibrx Biosciences (INBX) over the past year, losing 2.2% versus a loss of 17.8%. Inhibrx Biosciences is the larger company by market cap ($1.02 billion vs $791.6 million), about 1.3 times the size. Prime Medicine converts more of its revenue into profit, with a net margin of -4342.4% versus -10773.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INBX | PRME |
|---|---|---|
| Share price | $68.97 | $3.55 |
| Market cap | $1.02B | $791.62M |
| 1-day change | -7.21% | -7.55% |
| YTD return | -12.70% | +2.31% |
| 1-year return | -17.82% | -2.20% |
| EPS (TTM) | $-9.06 | $-0.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.30M | $4.63M |
| Revenue growth (YoY) | +550.00% | +55.28% |
| Net income (latest FY) | $-140.06M | $-201.14M |
| Operating margin | -10386.54% | -4498.06% |
| Net margin | -10773.46% | -4342.44% |
| 52-week high | $155.29 | $5.91 |
| 52-week low | $57.30 | $2.67 |
| Distance from 52-week high | -55.59% | -39.93% |
| Analyst consensus | none | buy |
| Avg. price target upside | +286.65% | +108.17% |
| Average volume | 305.96K | 4.64M |
| Shares outstanding | 14.77M | 222.99M |
| Employees | 109 | 146 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRME has outperformed INBX by 15.6 percentage points over the past year.
- Prime Medicine is more profitable, keeping -4342.4 cents of every revenue dollar as net income versus -10773.5 cents for Inhibrx Biosciences.
- Inhibrx Biosciences grew revenue faster in its latest fiscal year (+550.00% vs +55.28%).
About Inhibrx Biosciences
INBX stock →Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees
About Prime Medicine
PRME stock →Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 146 employees
INBX vs PRME FAQ
Which is bigger, Inhibrx Biosciences or Prime Medicine?
Inhibrx Biosciences (INBX) is larger, with a market capitalization of $1.02B compared with $791.62M for Prime Medicine (PRME).
Which stock has performed better over the past year, INBX or PRME?
PRME returned -2.20% over the past 12 months, compared with -17.82% for INBX (price return, excluding dividends). Past performance does not predict future results.
Are Inhibrx Biosciences and Prime Medicine in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.